TY - JOUR
T1 - Postoperative Pulmonary Complications in the ENIGMA II Trial
T2 - A Post Hoc Analysis
AU - Peyton, Philip J.
AU - Liskaser, Grace
AU - Ho, Alexander
AU - Marsh, Harry
AU - Etherington, Christopher
AU - Torlot, Frederick
AU - Desai, Manisha
AU - Perrett, George
AU - Chee, Brian
AU - Leslie, Kate
AU - Myles, Paul S.
N1 - Funding Information:
The ENIGMA II trial was a large, multicenter, international randomized trial ( ClinicalTrials.gov identifier NCT00430989) funded by the Australian National Health and Medical Research Council (grant No. GNT436677) and led by the Australian and New Zealand College of Anaesthetists Clinical Trials Network between 2007 and 2013. Eligible patients were adults aged at least 45 yr who were at risk of cardiovascular complications and who were having noncardiac surgery under general anesthesia that was expected to last more than 2 h. Cardiac risk factors included a history of coronary artery disease, heart failure, cerebrovascular disease, or peripheral vascular disease or older age (70 yr old or older) with other comorbidities. With written informed consent, patients were randomized to receive general anesthesia including a gas mixture containing a fraction of inspired oxygen (F io ) of 0.3 in either nitrogen or nitrous oxide. Patients in whom a higher intraoperative F io was planned, including those having thoracic surgery requiring one-lung ventilation, and patients with substantially impaired lung gas exchange were excluded. A high compliance rate with treatment allocation was achieved in the trial, with only 0.5% of those patients randomized to the nitrous oxide group failing to receive the allocated gas mixture. 2 2
Funding Information:
Dr. Peyton has received funding from Getinge (Solna, Sweden) and Maquet Critical Care (Solna, Sweden) for an unrelated project. The other authors declare no competing interests.
Publisher Copyright:
© 2023 Authors. All rights reserved.
PY - 2023/4/1
Y1 - 2023/4/1
N2 - Background: Nitrous oxide promotes absorption atelectasis in poorly ventilated lung segments at high inspired concentrations. The Evaluation of Nitrous oxide In the Gas Mixture for Anesthesia (ENIGMA) trial found a higher incidence of postoperative pulmonary complications and wound sepsis with nitrous oxide anesthesia in major surgery compared to a fraction of inspired oxygen of 0.8 without nitrous oxide. The larger ENIGMA II trial randomized patients to nitrous oxide or air at a fraction of inspired oxygen of 0.3 but found no effect on wound infection or sepsis. However, postoperative pulmonary complications were not measured. In the current study, post hoc data were collected to determine whether atelectasis and pneumonia incidences were higher with nitrous oxide in patients who were recruited to the Australian cohort of ENIGMA II. Methods: Digital health records of patients who participated in the trial at 10 Australian hospitals were examined blinded to trial treatment allocation. The primary endpoint was the incidence of atelectasis, defined as lung atelectasis or collapse reported on chest radiology. Pneumonia, as a secondary endpoint, required a diagnostic chest radiology report with fever, leukocytosis, or positive sputum culture. Comparison of the nitrous oxide and nitrous oxide-free groups was done according to intention to treat using chi-square tests. Results: Data from 2,328 randomized patients were included in the final data set. The two treatment groups were similar in surgical type and duration, risk factors, and perioperative management recorded for ENIGMA II. There was a 19.3% lower incidence of atelectasis with nitrous oxide (171 of 1,169 [14.6%] vs. 210 of 1,159 [18.1%]; odds ratio, 0.77; 95% CI, 0.62 to 0.97; P = 0.023). There was no difference in pneumonia incidence (60 of 1,169 [5.1%] vs. 52 of 1159 [4.5%]; odds ratio, 1.15; 95% CI, 0.77 to 1.72; P = 0.467) or combined pulmonary complications (odds ratio, 0.84; 95% CI, 0.69 to 1.03; P = 0.093). Conclusions: In contrast to the earlier ENIGMA trial, nitrous oxide anesthesia in the ENIGMA II trial was associated with a lower incidence of lung atelectasis, but not pneumonia, after major surgery.
AB - Background: Nitrous oxide promotes absorption atelectasis in poorly ventilated lung segments at high inspired concentrations. The Evaluation of Nitrous oxide In the Gas Mixture for Anesthesia (ENIGMA) trial found a higher incidence of postoperative pulmonary complications and wound sepsis with nitrous oxide anesthesia in major surgery compared to a fraction of inspired oxygen of 0.8 without nitrous oxide. The larger ENIGMA II trial randomized patients to nitrous oxide or air at a fraction of inspired oxygen of 0.3 but found no effect on wound infection or sepsis. However, postoperative pulmonary complications were not measured. In the current study, post hoc data were collected to determine whether atelectasis and pneumonia incidences were higher with nitrous oxide in patients who were recruited to the Australian cohort of ENIGMA II. Methods: Digital health records of patients who participated in the trial at 10 Australian hospitals were examined blinded to trial treatment allocation. The primary endpoint was the incidence of atelectasis, defined as lung atelectasis or collapse reported on chest radiology. Pneumonia, as a secondary endpoint, required a diagnostic chest radiology report with fever, leukocytosis, or positive sputum culture. Comparison of the nitrous oxide and nitrous oxide-free groups was done according to intention to treat using chi-square tests. Results: Data from 2,328 randomized patients were included in the final data set. The two treatment groups were similar in surgical type and duration, risk factors, and perioperative management recorded for ENIGMA II. There was a 19.3% lower incidence of atelectasis with nitrous oxide (171 of 1,169 [14.6%] vs. 210 of 1,159 [18.1%]; odds ratio, 0.77; 95% CI, 0.62 to 0.97; P = 0.023). There was no difference in pneumonia incidence (60 of 1,169 [5.1%] vs. 52 of 1159 [4.5%]; odds ratio, 1.15; 95% CI, 0.77 to 1.72; P = 0.467) or combined pulmonary complications (odds ratio, 0.84; 95% CI, 0.69 to 1.03; P = 0.093). Conclusions: In contrast to the earlier ENIGMA trial, nitrous oxide anesthesia in the ENIGMA II trial was associated with a lower incidence of lung atelectasis, but not pneumonia, after major surgery.
UR - http://www.scopus.com/inward/record.url?scp=85149493686&partnerID=8YFLogxK
U2 - 10.1097/ALN.0000000000004497
DO - 10.1097/ALN.0000000000004497
M3 - Article
C2 - 36645804
AN - SCOPUS:85149493686
SN - 0003-3022
VL - 138
SP - 354
EP - 363
JO - Anesthesiology
JF - Anesthesiology
IS - 4
ER -